Florida Plaintiffs Say Takeda Should Have Warned Users About Actos Bladder Cancer
In a new Actos side effects lawsuit, Florida residents Abdul and Barbara Raoufi say Actos manufacturer Takeda Pharmaceuticals should have made an effort to warn users of the diabetes drug about the risk of developing Actos bladder cancer.
Actos was approved by the Food and Drug Administration (FDA) to treat symptoms related to type 2 diabetes. Unfortunately, it’s also been linked to an increased risk of bladder cancer, especially when taken for 12 or more months.
In their Actos lawsuit, Abdul F. Raoufi and Barbara L. Raoufi vs. Takeda Pharmaceuticals, Abdul Raoufi says he developed Actos bladder cancer in 2007. He accuses the drug company of failing to warn him and other consumers about the risk of taking Actos.
His Actos lawsuit was filed April 16, 2012 in the Circuit Court, Cook County Illinois.
Causes, symptoms and treatment of Actos bladder cancer
The risk of developing Actos bladder cancer increases by about 40 percent in individuals taking the medication for more than 12 months. While researchers do not know why Actos causes bladder cancer, they believe it may be linked genetic defects that develop when the drug is taken over a long period of time.
Symptoms of Actos cancer include blood in the urine, pain during urination, and the frequent need to urinate.
Actos cancer may be treated through chemotherapy, radiation therapy, the partial or complete removal of the bladder, or biotherapy, which uses the immune system to strengthen a patient’s defense against cancer.
Other Actos side effects include Actos heart failure.
FDA, European markets warn of Actos cancer
Although Raoufi’s Actos side effects lawsuit accuses Takeda of failing to warn consumers about the risk of developing bladder cancer, the FDA and European medical experts have alerted the public about this risk.
In June 2011, two years after approving Actos, the FDA issued a public health communication stating that those who take Actos for more than 12 months face a 40 percent greater risk of developing Actos cancer than those who use it during a shorter period of time.
Government-funded studies in France and Germany linking Actos use to bladder cancer prompted regulators in both countries to pull the drug from the shelves. Although the FDA has not issued an Actos recall, consumers in several states including Florida, Oregon and Connecticut have filed litigation seeking damages related to their claims of Actos cancer.